NCPE Recommends Vabysmo, Signaling Retinal Policy Shift
NCPE recommends Vabysmo for neovascular (wet) age-related macular degeneration treatment.
NCPE recommends Vabysmo for neovascular (wet) age-related macular degeneration treatment.
New partnership advances reimbursement strategy for private practices.
Medicare exoskeleton coverage approved for ReWalk Personal Exoskeleton, sets key precedent.
South Korea’s new pharma pricing reforms reward innovation and expand access for industry.
Quick Summary: NICE has published new interventional procedures guidance recommending the use of transcatheter aortic valve implantation (TAVI) for patients with native aortic valve regurgitation. This guidance enables wider access to TAVI as a less invasive alternative to open-heart surgery for eligible NHS patients, with a key focus on multidisciplinary team-based patient selection and … Read more
NICE empowers NHS with digital health tech for children’s mental health, boosting access and efficiency.
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.
GoodRx reshapes independent pharmacy economics through transparent cost-plus pricing model launch.
Major insurers endorse billing limits on controversial home-based risk assessments.
Regional HTA network addresses equity, economic evaluation, and adaptation frameworks.